RG2833

RG2833 is a brain-penetrant HDAC inhibitor with IC50s of 60 nM and 50 nM for HDAC1 and HDAC3, respectively. The Ki values for HDAC1 and HDAC3 are 32 and 5 nM, respectively[1].

Product Specifications

CAS Number

[1215493-56-3]

Product Name Alternative

RGFP109

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rg2833.html

Purity

99.26

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(NCCCCCC(NC1=CC=CC=C1N)=O)C2=CC=C(C)C=C2

Molecular Formula

C20H25N3O2

Molecular Weight

339.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Rai M, et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One. 2010, 5 (1), e8825.|[2]Sandi C, et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis. 2011, 42 (3), 496-505.|[3]Johnston TH, et al. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study. Parkinsonism Relat Disord. 2013, 19 (2), 260-264.